Influenza

Seasonal influenza viruses infect 5-15% of the population worldwide annually. In addition, pandemic flu strains have been responsible for several global outbreaks in the past century and have resulted in significant morbidity and mortality. Flu vaccines have reduced the incidence of seasonal flu in the general population, however these have not been as effective in people with compromised immune systems such as the elderly.

XBiotech is developing a True Human™ antibody against Influenza and is actively screening antibody candidates for their ability to broadly neutralize multiple seasonal and pandemic virus strains. Lead candidates are being tested in vitro and in vivo animal models.